EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab

Kyosuke Hattori iD, Yasuhide Kanayama

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Kyosuke Hattori und 1 weiteren Autor:innen. Beteiligte Einrichtung: Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Aichi, Japan. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Bone Density, Procollagen, Antibodies, Monoclonal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The present study aimed to investigate the effectiveness of treatment with romosozumab for 1 year and association between bone turnover markers and changes in bone mineral density (BMD) in patients with postmenopausal osteoporosis.

Methods

Participants were 53 treatment-naïve postmenopausal osteoporosis patients. Correlations of per cent changes (Δ) in lumbar (L) and total hip (TH) BMD 12 months after initiating romosozumab with baseline demographic factors and parameters of N-terminal propeptide of Type 1 collagen (P1NP) and tartrate-resistant acid phosphatase-5b at baseline and Months 1, 3, and 6 were assessed. Multiple regression analysis was performed on factors significantly correlated with ΔL-BMD and ΔTH-BMD at Month 12.

Results

ΔL-BMD and ΔTH-BMD at Month 12 were 17.5% and 8.1%, respectively. Multiple regression analysis revealed that a high P1NP value at Month 3 predicted large increases in L-BMD and TH-BMD at Month 12. High total amount of P1NP values from baseline to Month 6 was associated with large increases in L-BMD and TH-BMD at Month 12 and was most strongly correlated with the P1NP value at Month 3.

Conclusions

A high P1NP value at Month 3 predicted large increases in both L-BMD and TH-BMD at Month 12 in postmenopausal osteoporosis patients treated with romosozumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporosis, PostmenopausalBone DensityProcollagenAntibodies, MonoclonalBone Density Conservation AgentsHumansFemaleAgedMiddle AgedPeptide FragmentsTreatment OutcomeBiomarkersBone RemodelingLumbar Vertebrae

Stichwörter der Autor:innen

N-terminal propeptide of Type 1 collagenPostmenopausal osteoporosisgoal-directed treatmentromosozumabtreat to target

Substanzen

romosozumabProcollagenAntibodies, MonoclonalBone Density Conservation Agentsprocollagen Type I N-terminal peptidePeptide FragmentsBiomarkers

Autor:innen und Institutionen

  • Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Aichi, Japan.

ORCID-Profile: Kyosuke Hattori

Zitieren

APA

Hattori, K., & Kanayama, Y. (2024). Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab. Modern Rheumatology. https://doi.org/10.1093/mr/roae008

Vancouver

Hattori K, Kanayama Y. Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab. Modern Rheumatology. 2024. doi:10.1093/mr/roae008

BibTeX
@article{Hattori2024,
  author = {Hattori, Kyosuke and Kanayama, Yasuhide},
  title = {Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae008}
}
Kostenlos starten →